Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Shares Shorted: Short Interest Up 229.2% in October

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) saw a significant increase in short interest in October. As of October 30th, there was short interest totaling 9,890 shares, an increase of 229.2% from the October 15th total of 3,004 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 25,967 shares, the days-to-cover ratio is presently 0.4 days.

Emmaus Life Sciences Stock Performance

Shares of EMMA stock remained flat at $0.02 on Thursday. 19,000 shares of the stock traded hands, compared to its average volume of 17,983. Emmaus Life Sciences has a one year low of $0.01 and a one year high of $0.09. The company has a fifty day simple moving average of $0.05 and a two-hundred day simple moving average of $0.02. The firm has a market cap of $1.54 million, a price-to-earnings ratio of -0.24 and a beta of 11.25.

Emmaus Life Sciences (OTCMKTS:EMMA) last posted its earnings results on Friday, August 14th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $6.32 million for the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and debilitating diseases. The company’s best-known product is Endari, an oral powder formulation of L-glutamine approved in the United States to reduce the frequency of acute complications associated with sickle cell disease in adults and children aged five and older. Emmaus has focused its research and development activities on therapies for diseases with significant unmet medical needs, including hematological and other rare disorders.